Cardiovascular Revascularization Medicine
Volume 13, Issue 1 , Pages 11-19 , January 2012

The role of oxidized phospholipids, lipoprotein (a) and biomarkers of oxidized lipoproteins in chronically occluded coronary arteries in sudden cardiac death and following successful percutaneous revascularization

  • Paul Fefer

      Affiliations

    • Schulich Heart Center, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada M4N 3M5
    • Current address: Sheba Medical Center, Tel Aviv University, Tel Aviv.
    • ,
  • Sotirios Tsimikas

      Affiliations

    • Vascular Medicine Program, University of California, San Diego, USA
    • ,
  • Amit Segev

      Affiliations

    • St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada
    • Current address: Sheba Medical Center, Tel Aviv University, Tel Aviv.
    • ,
  • John Sparkes

      Affiliations

    • Schulich Heart Center, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada M4N 3M5
    • ,
  • Fumiyuki Otsuma

      Affiliations

    • CVPath Institute, Gaithersburg, MD, USA
    • ,
  • Frank Kolodgie

      Affiliations

    • CVPath Institute, Gaithersburg, MD, USA
    • ,
  • Renu Virmani

      Affiliations

    • CVPath Institute, Gaithersburg, MD, USA
    • ,
  • Joseph Juliano

      Affiliations

    • Vascular Medicine Program, University of California, San Diego, USA
    • ,
  • Thierry Charron

      Affiliations

    • St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada
    • Current address: Hôpital du Sacré-Coeur de Montréal, Montréal, Québec.
    • ,
  • Bradley H. Strauss

      Affiliations

    • Schulich Heart Center, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada M4N 3M5
    • Corresponding Author InformationCorresponding author. Schulich Heart Center, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada M4N 3M5. Tel.: +1 416 480 6066; fax: +1 416 480 4745.

Received 17 April 2011 ,Revised 5 August 2011 ,Accepted 15 August 2011.

References 

  1. Palinski W, Rosenfeld ME, Ylä-Herttuala S, Gurtner GC, Socher SS, Butler SW, et al. Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci U S A. 1989;86:1372–1376
  2. Tsimikas S, Palinski W, Halpern SE, Yeung DW, Curtiss LK, Witztum JL. Radiolabeled MDA2, an oxidation-specific, monoclonal antibody, identifies native atherosclerotic lesions in vivo. J Nucl Cardiol. 1999;6:41–53
  3. Ylä-Herttuala S, Palinski W, Rosenfeld ME, Parthasarathy S, Carew TE, Butler S, et al. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest. 1989;84:1086–1095
  4. Witztum JL, Steinberg D. The oxidative modification hypothesis of atherosclerosis: does it hold for humans?. Trends Cardiovasc Med. 2001;11:93–102
  5. Ehara S, Ueda M, Naruko T, Haze K, Itoh A, Otsuka M, et al. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation. 2001;103:1955–1960
  6. Nishi K, Itabe H, Uno M, Kitazato KT, Horiguchi H, Shinno K, et al. Oxidized LDL in carotid plaques and plasma associates with plaque instability. Arterioscler Thromb Vasc Biol. 2002;22:1649–1654
  7. Burke A, Cresswell N, Kolodgie F, Virmani R, Tsimikas S. Increased expression of oxidation-specific epitopes and Lp(a) reflect unstable plaques in human coronary arteries. J Am Coll Cardiol. 2008;49:A299
  8. Dangas G, Mehran R, Harpel PC, Sharma SK, Marcovina SM, Dube G, et al. Lipoprotein(a) and inflammation in human coronary atheroma: Association with the severity of clinical presentation. J Am Coll Cardiol. 1998;32:2035–2204
  9. Tsimikas S, Bergmark C, Beyer RW, Patel R, Pattison J, Miller E, et al. Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. J Am Coll Cardiol. 2003;41:360–370
  10. Holvoet P, Collen D, Van de Werf F. Malondialdehyde-modified LDL as a marker of acute coronary syndromes. JAMA. 1999;281:1718–1721
  11. Tamai O, Matsuoka H, Itabe H, Wada Y, Kohno K, Imaizumi T. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation. 1997;95:76–82
  12. Penny WF, Ben-Yehuda O, Kuroe K, Long J, Bond A, Bhargava V, et al. Improvement of coronary artery endothelial dysfunction with lipid-lowering therapy: heterogeneity of segmental response and correlation with plasma-oxidized low density lipoprotein. J Am Coll Cardiol. 2001;37:766–774
  13. Ahmadi N, Tsimikas S, Hajsadeghi F, Saeed A, Nabavi V, Bevinal MA, et al. Relation of oxidative biomarkers, vascular dysfunction, and progression of coronary artery calcium. Am J Cardiol. 2010;105:459–466
  14. Kahn JK. Angiographic suitability for catheter revascularization of total coronary occlusions in patients from a community hospital setting. Am Heart J. 1993;126:561–564
  15. Srivatsa SS, Edwards WD, Boos CM, Grill DE, Sangiorgi GM, Garratt KN, et al. Histologic correlates of angiographic chronic total coronary artery occlusions: influence of occlusion duration on neovascular channel patterns and intimal plaque composition. J Am Coll Cardiol. 1997;29:955–963
  16. Tsimikas S, Lau HK, Han KR, Shortal B, Miller ER, Segev A, et al. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein. Circulation. 2004;109:3164–3170
  17. Ravandi A, Harkewicz R, Leibundgut G, Miller YI, Dennis EA, Witztum JL, et al. Identification of oxidized phospholipids and cholesteryl esters in embolic protection devices post percutaneous coronary, carotid and peripheral interventions in humans. Arterioscler Thromb Vasc Biol. 2011;P385
  18. Tsimikas S, Miller YI. Oxidative modification of lipoproteins: mechanisms, role in inflammation and potential clinical applications in cardiovascular disease. Current Pharmaceutical Design. 2011;17:27–37
  19. Tsimikas S, Mallat Z, Talmud PJ, Kastelein JJ, Wareham NJ, Sandhu MS, et al. Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events. J Am Coll Cardiol. 2010;56:946–955
  20. Tsimikas S, Witztum JL. The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity. Current Opinion in Lipidology. 2008;19:369–377
  21. Kramer MC, Rittersma SZ, de Winter RJ, Ladich ER, Fowler DR, Liang YH, et al. Relationship of thrombus healing to underlying plaque morphology in sudden coronary death. J Am Coll Cardiol. 2010;55:122–132
  22. Miner SE, Hegele RA, Sparkes J, Teitel JM, Bowman KA, Connelly PW, et al. Homocysteine, lipoprotein(a), and restenosis after percutaneous transluminal coronary angioplasty: a prospective study. Am Heart J. 2000;140:272–278
  23. Strauss BH, Lau HK, Bowman KA, Sparkes J, Chisholm RJ, Garvey MB, et al. Plasma urokinase antigen and plasminogen activator inhibitor-1 antigen levels predict angiographic coronary restenosis. Circulation. 1999;100:1616–1622
  24. Farb A, Weber DK, Kolodgie FD, Burke AP, Virmani R. Morphological predictors of restenosis after coronary stenting in humans. Circulation. 2002;105:2974–2980
  25. Friedman P, Horkko S, Steinberg D, Witztum JL, Dennis EA. Correlation of antiphospholipid antibody recognition with the structure of synthetic oxidized phospholipids. Importance of schiff base formation and aldol condensation. J Biol Chem. 2002;277:7010–7020
  26. Shaw PX, Horkko S, Tsimikas S, Chang MK, Palinski W, Silverman GJ, et al. Human-derived anti-oxidized ldl autoantibody blocks uptake of oxidized ldl by macrophages and localizes to atherosclerotic lesions in vivo. Arterioscler Thromb Vasc Biol. 2001;21:1333–1339
  27. Miller YI, Choi SH, Wiesner P, Fang L, Harkewicz R, Hartvigsen K, et al. Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity. Circ Res. 2011;108:235–248
  28. Stone GW, Kandzari DE, Mehran R, Colombo A, Schwartz RS, Bailey S, et al. Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: part I. Circulation. 2005;112:2364–2372
  29. Bergmark C, Dewan A, Orsoni A, Merki E, Miller ER, Shin MJ, et al. A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma. J Lipid Res. 2008;49:2230–2239
  30. Gottsauner-Wolf M, Zasmeta G, Hornykewycz S, Nikfardjam M, Stepan E, Wexberg P, et al. Plasma levels of C-reactive protein after coronary stent implantation. Eur Heart J. 2000;21:1152–1158
  31. Kim JY, Ko YG, Shim CY, Park S, Hwang KC, Choi D, et al. Comparison of effects of drug-eluting stents versus bare metal stents on plasma C-reactive protein levels. Am J Cardiol. 2005;96:1384–1388
  32. Tsimikas S, Aikawa M, Miller FJ, Miller ER, Torzewski M, Lentz SR, et al. Increased plasma oxidized phospholipid: apolipoprotein b-100 ratio with concomitant depletion of oxidized phospholipids from atherosclerotic lesions after dietary lipid-lowering: a potential biomarker of early atherosclerosis regression. Arterioscler Thromb Vasc Biol. 2007;27:175–181
  33. Tsimikas S. In vivo markers of oxidative stress and therapeutic interventions. Am J Cardiol. 2008;101:34D–42D
  34. Anuurad E, Boffa MB, Koschinsky ML, Berglund L. Lipoprotein(a): a unique risk factor for cardiovascular disease. Clin Lab Med. 2006;26:751–772

☆ Disclosure: Dr Tsimikas is named as co-inventor of patents and patent applications related to oxidation-specific antibodies, has equity interest in Atherotope, and is a consultant to Quest Diagnostics. The other authors declare no conflicts of interest.

PII: S1553-8389(11)00501-X

doi: 10.1016/j.carrev.2011.08.001

Cardiovascular Revascularization Medicine
Volume 13, Issue 1 , Pages 11-19 , January 2012

Article Tools

* Image Usage & Resolution